Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Exelixis, Inc. reported its financial results for the fourth quarter and full year 2025, illustrating significant developments and setting the stage for potential growth in 2026.</li><li>The company is focused on expanding its leadership in solid tumor oncology, leveraging its established presence in GU oncology and aiming to extend this to GI indications.</li><li>For the fiscal year 2025, Exelixis recorded U.S. net product revenues from its cabozantinib franchise at approximately $2.12 billion, a 17% increase from 2024, with fourth-quarter revenues reaching $547 million, marking a 6% year-over-year growth.</li></ul>

Exelixis, Inc. reported its financial results for the fourth quarter and full year 2025, illustrating significant developments and setting the stage for potential growth in 2026.The company is focused on expanding its leadership in solid tumor oncology, leveraging its established presence in GU oncology and aiming to extend this to GI indications.For the fiscal year 2025, Exelixis recorded U.S. net product revenues from its cabozantinib franchise at approximately $2.12 billion, a 17% increase from 2024, with fourth-quarter revenues reaching $547 million, marking a 6% year-over-year growth.

Partnership Power at Exelixis: Leveraging Collaborations to De-Risk Clinical Expansion!

Exelixis Inc

Partnership Power at Exelixis: Leveraging Collaborations to De-Risk Clinical Expansion!